Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

Medicina, Free Full-Text

Pharmacotherapies of NAFLD: updated opportunities based on

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Diseases, Free Full-Text

Inhibition of MGAT2 modulates fat‐induced gut peptide release and

Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2

The effect of CpdB on diabetes and obesity in HFD‐fed ob/ob mice

Metabolomics combined with network pharmacology exploration

US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Novel antisense inhibition of diacylglycerol O-acyltransferase 2